tarlatamab + YL201

This is a **combination investigational therapy** for small cell lung cancer (SCLC) currently under clinical evaluation. - **Tarlatamab** is a bispecific T-cell engager that targets **Delta-like ligand 3 (DLL3)** on tumor cells and **CD3** on T cells, facilitating T-cell mediated cytotoxicity against DLL3-expressing cancer cells[6][2]. - **YL201** is an antibody-drug conjugate (ADC) that targets **B7 homolog 3 (B7-H3)**, using a human anti-B7H3 monoclonal antibody linked to a novel topoisomerase 1 inhibitor payload via a protease-cleavable linker[8]. Both agents are being developed for **extensive-stage small cell lung cancer (ES-SCLC)** in patients who have progressed after platinum-based therapy[1][5][3][7]. The combination is being evaluated with or without anti-PD-L1 (such as atezolizumab or durvalumab) in a Phase 1b trial (DeLLphi-310), primarily to assess safety and tolerability in this population[1][5][3][7].

Other names

tarlatamab-dlleB7H3 ADC (for YL201)DLL3/CD3 bispecific T-cell engager (for tarlatamab)